Vanguard Group Inc. Has $3.62 Billion Stake in DexCom, Inc. (NASDAQ:DXCM)

Vanguard Group Inc. cut its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 1.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 46,530,017 shares of the medical device company’s stock after selling 904,784 shares during the quarter. Vanguard Group Inc. owned about 11.91% of DexCom worth $3,618,639,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of DXCM. Versant Capital Management Inc acquired a new stake in DexCom during the 4th quarter worth about $25,000. Private Trust Co. NA boosted its position in shares of DexCom by 266.3% during the 4th quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock valued at $26,000 after purchasing an additional 245 shares in the last quarter. TD Private Client Wealth LLC grew its stake in DexCom by 62.8% during the fourth quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company’s stock worth $34,000 after purchasing an additional 167 shares during the period. Larson Financial Group LLC increased its holdings in DexCom by 40.5% in the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company’s stock worth $37,000 after purchasing an additional 137 shares in the last quarter. Finally, Heck Capital Advisors LLC acquired a new position in DexCom in the fourth quarter valued at approximately $38,000. Institutional investors own 97.75% of the company’s stock.

DexCom Stock Up 2.1 %

DexCom stock opened at $75.32 on Tuesday. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $142.00. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. The firm’s 50-day simple moving average is $83.24 and its 200 day simple moving average is $77.07. The stock has a market cap of $29.43 billion, a PE ratio of 52.67, a price-to-earnings-growth ratio of 2.30 and a beta of 1.28.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. Research analysts predict that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Insider Buying and Selling at DexCom

In related news, CEO Kevin R. Sayer sold 33,359 shares of the stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the completion of the transaction, the chief executive officer now owns 319,037 shares in the company, valued at approximately $27,727,505.67. This represents a 9.47 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Jacob Steven Leach sold 14,076 shares of the firm’s stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total transaction of $990,668.88. Following the sale, the chief operating officer now owns 313,497 shares of the company’s stock, valued at $22,063,918.86. This trade represents a 4.30 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 105,009 shares of company stock worth $8,044,178 in the last quarter. 0.30% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on DXCM shares. Morgan Stanley lifted their price objective on shares of DexCom from $75.00 to $82.00 and gave the company an “equal weight” rating in a research note on Friday, February 14th. Wells Fargo & Company reiterated an “overweight” rating on shares of DexCom in a report on Saturday, March 8th. Robert W. Baird upgraded DexCom from a “neutral” rating to an “outperform” rating and raised their target price for the company from $86.00 to $104.00 in a research note on Thursday, January 16th. Canaccord Genuity Group upped their price target on DexCom from $99.00 to $103.00 and gave the stock a “buy” rating in a research note on Friday, February 14th. Finally, Citigroup raised their price objective on DexCom from $101.00 to $104.00 and gave the company a “buy” rating in a research note on Tuesday, March 4th. Four analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, DexCom currently has an average rating of “Moderate Buy” and an average price target of $99.82.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.